$12M Vioxx Deal Requires Merck To Add Safety Checks

Law360, New York (February 10, 2010, 3:07 PM EST) -- A New Jersey state judge has preliminarily approved a settlement of a Vioxx-related shareholder derivative action that will see Merck & Co. Inc. institute stronger drug-safety measures, appoint a chief medical officer and pay nearly $12.2 million in attorneys' fees.

An unnamed judge of the Superior Court of New Jersey, Atlantic County Division, gave a preliminary sign-off on the settlement Monday, according to a filing with the U.S. Securities and Exchange Commission. If the deal gets final approval, all shareholder derivative litigation stemming from the discontinued...
To view the full article, register now.